Effects of the SRC Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Phase I Trial

Journal of Bone and Mineral Research - United States
doi 10.1359/jbmr.090830

Related search